生物学指标C-erbB-2、p53基因、Cath-D及组织学分级评判转移性乳腺癌化疗的价值

下载PDF

导出

作者张伟芳何晶

机构地区常州市妇幼保健医院乳房外科常州市妇幼保健医院病理科

出处《南京医科大学学报（自然科学版）》 CAS CSCD 北大核心 2001年第4期362-363,共2页 Journal of Nanjing Medical University(Natural Sciences)

关键词组织学分级转移性乳腺癌化疗疗效治疗 C-ERB-2 P53基因 CATH-D

参考文献4

1Harbeck N,Alt U,Berger U. et al.Long-term follow-up corfirms prognostic impact of Cath-D in primary breast cancer[].International Journal of Biological Markers.2000
2Van Slooten HJ,Van De Vijver MJ,Borresen AL,et al.Mutations in exons 5-8 of the p53 gene, independent of their type and location with increased apoptosis and mitosis in invasive breast cancer[].Journal of Paleopathology.1999
3Cheung KL,Pinder SE,Paish C. et al.The role of blood tumor marker measurement (using a biochemical index score and C-erbB2)in directing chemotherapy in metastatic breast cancer[].International Journal of Biological Markers.2000
4Makris A,Powles T J,Dowsett M,et al.P53 protein overexpression and chemosensitivity in breast cancer[].The Lancet.1995

南京医科大学学报（自然科学版）

2001年第4期

内容加载中请稍等...